Posted by Michael Wonder on 16 Jun 2023
Chugai files new drug application in Japan for crovalimab for paroxysmal nocturnal hemoglobinuria
16 June 2023 - The application was submitted based on several studies, including the global Phase 3 clinical studies COMMODORE 2 and COMMODORE 1.
Chugai Pharmaceutical announced that it filed regulatory applications with the Ministry of Health, Labour and Welfare for the anti-C5 antibody crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria on 14 June 2023.
